Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Parallel-group, Double-blind, Placebo-controlled Study of Methylphenidate as an Add on Therapy for Mirtazapine in the Treatment of Major Depressive Disorder in Cancer Patients Under Palliative Care
Brief Summary: Primary Objective To determine the efficacy of Methylphenidate as add on therapy to mirtazapine in the treatment of depression in cancer patients under palliative care Hypothesis Methyphenidate add on to mirtazapine treated subjects will show significant early reduction in (Montgomery Asberg Depression Rating Scale) MADRS between baseline and Day 3.

Secondary Objective

1. To determine the efficacy of Methylphenidate as add on therapy to mirtazapine in the treatment of anxiety in cancer patients under palliative care.

   Hypothesis Methyphenidate add on to mirtazapine treated subjects will show significant early reduction in anxiety score of HADS than Mirtazepine alone treated subjects between baseline and Day 3.
2. To determine the efficacy of Methylphenidate as add on therapy to mirtazapine in reducing distress in cancer patients under palliative care.

   Hypothesis Methyphenidate add on to mirtazapine treated subjects will show significant early reduction in distress score of distress thermometer than Mirtazepine alone treated subjects between baseline and Day 3.
3. To determine the efficacy of Methylphenidate as add on therapy to mirtazapine in improving function in cancer patients under palliative care.

   Hypothesis Methyphenidate add on to mirtazapine treated subjects will show increase in the (Eastern Cooperation Group performance status) ECOG score than Mirtazepine alone treated subjects between baseline and Day 3
4. To determine the efficacy of Methylphenidate as add on therapy to mirtazapine in reducing somatic complaints in cancer patients under palliative care.

Hypothesis Methyphenidate add on to mirtazapine treated subjects will show significant early reduction in the score of Numeric Rating Scale (NRS) for Pain and Visual Analogue Scale (VAS) for Fatigue than Mirtazapine alone treated subjects between baseline and Day 3.


Options:
A: Arm Label: Arm I - Placebo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Placebo Powder, Drug: Placebo Pill | Arm Label: Arm II - Soy; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: oral soy protein/isoflavones powder, Drug: Placebo Pill | Arm Label: Arm III - Venlafaxine; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine, Dietary Supplement: Placebo Powder | Arm Label: Arm IV - Soy + Venlafaxine; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: oral soy protein/isoflavones powder, Drug: Venlafaxine | Intervention Type: DIETARY_SUPPLEMENT; Name: oral soy protein/isoflavones powder; Assigned to Arm(s): Arm II - Soy, Arm IV - Soy + Venlafaxine | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): Arm III - Venlafaxine, Arm IV - Soy + Venlafaxine | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo Powder; Assigned to Arm(s): Arm I - Placebo, Arm III - Venlafaxine | Intervention Type: DRUG; Name: Placebo Pill; Assigned to Arm(s): Arm I - Placebo, Arm II - Soy
B: Arm Label: Methylphenidate add on to Mirtazapine; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate | Arm Label: Placebo add on to Mirtazapine; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate add on to Mirtazapine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo add on to Mirtazapine
C: Arm Label: Arm I (management of therapy complications); Type: EXPERIMENTAL; Interventions: Drug: venlafaxine, Other: questionnaire administration, Other: quality-of-life assessment | Arm Label: Arm II (placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Other: questionnaire administration, Other: quality-of-life assessment | Intervention Type: DRUG; Name: venlafaxine; Assigned to Arm(s): Arm I (management of therapy complications) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Arm II (placebo) | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): Arm I (management of therapy complications), Arm II (placebo) | Intervention Type: OTHER; Name: quality-of-life assessment; Assigned to Arm(s): Arm I (management of therapy complications), Arm II (placebo)
D: Arm Label: Desipramine HCl; Type: EXPERIMENTAL; Interventions: Drug: Desipramine HCL | Intervention Type: DRUG; Name: Desipramine HCL; Assigned to Arm(s): Desipramine HCl

Answer: B